Multiple Myeloma in Relapse Completed Phase 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01083602Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple MyelomaTreatment